+1.212.901.8009 sclassen@alzdiscovery.org

13th ANNUAL DRUG DISCOVERY FOR NEURODEGENERATION CONFERENCE
An Educational Course on Translating Research into Drugs
Presented by the Alzheimer’s Drug Discovery Foundation
March 17-19, 2019 • Long Beach, CA

Program

All sessions will be held at the Renaissance Long Beach Hotel located at 111 East Ocean Boulevard, Long Beach, CA 90802.

The 2019 Preliminary Program will be posted soon!

 

Until then, please review the 2018 Program outlined below; videocasts of the presentations are available for review from the Videocasts page or from Vimeo.
 
 

2018 PROGRAM

SUNDAY, FEBRUARY 4, 2018
2:00pm - 5:00Registration
4:00 - 4:20Welcome & Opening Remarks: Challenges and Opportunities in Academic Drug Discovery
Howard Fillit, MD—Alzheimer’s Drug Discovery Foundation
4:20 - 5:00KEYNOTE: Executing a Drug Discovery Program with an Eventual Clinical Trial in Mind
Richard Mohs, PhD—Global Alzheimer’s Platform
5:00 - 5:10Q&A
5:10 - 7:00Welcoming Reception
MONDAY, FEBRUARY 5, 2018
7:30am - 8:30Breakfast
8:30 - 8:40Opening Remarks and ADDF Funding Opportunities
Andrew Koemeter-Cox, PhD—Alzheimer's Drug Discovery Foundation
8:40 - 8:50NIA Opportunities for Translational Research Funding
Lorenzo Refolo, PhD—National Institutes of Health, National Institute on Aging
8:50 - 9:00NINDS Opportunities for Translational Research Funding
Amir Tamiz, PhD—National Institutes of Health, National Institute of Neurological Disorders and Stroke
Session I. Embarking on a Drug Discovery Campaign
Chair: Marcie Glicksman, PhD—Orig3n, Inc.
9:00 - 9:05Session Overview:
Marcie Glicksman, PhD—Orig3n, Inc.
9:05 - 9:25What Makes a Good Translational Target?
Richard Margolin, MD—Pfizer, Inc.
9:25 - 9:35Q&A
9:35 - 9:55New Trends and Technology in Assay Development
Marcie Glicksman, PhD—Orig3n, Inc.
9:55 - 10:05Q&A
10:05 - 10:25Phenotypic Screening in Drug Discovery: An Industry Perspective
Claire Steppan, PhD—Pfizer, Inc.
10:25 - 10:35Q&A
10:35 - 11:00EXHIBITOR SESSION AND BREAK
Session II. Starting at the End: The Pharmacology—Chemistry Interface in Preclinical Drug Development
Chair: D. Martin Watterson, PhD—Northwestern University
11:00 - 11:05Session Overview:
D. Martin Watterson, PhD—Northwestern University
11:05 - 11:25Ask Your Chemist Which Chemical Series Is Right for You
Amy Ripka, PhD— Lucy Therapeutics
11:25 - 11:35Q&A
11:35 - 11:55PK/PD in Preclinical Development
Sharon Rosenzwieg-Lipson, PhD—AgeneBio, Inc.
11:55am - 12:05pmQ&A
12:05 - 12:25Integrating Smart Biology with Smart Chemistry: Risk Reduction Through Secondary Pharmacology and Exploratory Drug Safety
D. Martin Watterson, PhD—Northwestern University
12:25 - 12:35Q&A
12:35 - 12:45Young Investigator Scholarship Awards Presented
Nicholas McKeehan—Alzheimer’s Drug Discovery Foundation
12:45–1:15YOUNG INVESTIGATOR SCHOLARSHIP POSTER SESSION
Poster Abstracts #1-12
1:15 - 2:15LUNCH
Session III. Drug Discovery: From Lead to Clinical Candidate
Chair: Edward Spack, PhD—MedaRed, Inc.
2:15 - 2:20Session Overview:
Edward Spack, PhD—MedaRed, Inc.
2:20 - 2:40Drug Delivery for CNS Disease
William Banks, MD—VA/University of Washington
2:40 - 2:50Q&A
2:50 - 3:10Improving the Translatability of Animal Models of Neurodegeneration
Caroline Zeiss, BVSc, PhD—Yale University School of Medicine
3:10 - 3:20Q&A
3:20 - 3:40Integrating Biomarkers into Drug Discovery and Development for Increased Changes of Success
Kenneth Marek, MD—The Institute for Neurodegenerative Disorders
3:40 - 3:50Q&A
3:50 - 4:10Requirements for an IND
Edward Spack, PhD—MedaRed, Inc.
4:10 - 4:20Q&A
4:20 - 4:40ADDF Access
Lauren Friedman, PhD—Alzheimer’s Drug Discovery Foundation
4:50 - 5:50Partnering/Mentoring Session (pre-registration required)
4:40 - 6:40Networking Reception
TUESDAY, FEBRUARY 6, 2018
7:30am - 8:00Partnering/Mentoring Session (pre-registration required)
7:30 - 8:20Continental Breakfast
8:20 - 8:25Welcome & Opening Remarks
Lauren Friedman, PhD—Alzheimer’s Drug Discovery Foundation
8:25 - 9:05KEYNOTE:
Changing Ecosystem of Drug Discovery: Rising Role of Academia and Academic-Pharma Partnerships in the Development of New Therapeutics

Barbara Slusher, PhD—Johns Hopkins University School of Medicine
9:05 - 9:15Q&A
Session IV. Strategies for Challenging CNS Targets—Case Study Examples
Chair: Kurt Brunden, PhD—University of Pennsylvania
9:15 - 9:20Session Overview:
Kurt Brunden, PhD—University of Pennsylvania
9:20 - 9:40Microtubule Stabilizing Compounds for Neurodegenerative Diseases
Kurt Brunden, PhD—University of Pennsylvania
9:40 - 9:50Q&A
9:50 - 10:10Imaging Inflammation in Patients with Alzheimer’s Disease or Dementia with Lewy Bodies
William Kreisl, MD—Taub Institute, Columbia University
10:10 - 10:20Q&A
10:20 - 10:50EXHIBITOR SESSION AND BREAK
10:50 - 11:10Clinical Development of a Selective PDE4D Inhibitor
Mark Gurney, PhD—Tetra Discovery Partners
11:10 - 11:20Q&A
11:20 - 11:40Neurophysiological Biomarkers for Neurodegenerative Disease Drug Development
Daniel Javitt, MD, PhD—Columbia University Medical Center
11:40 - 11:50Q&A
11:50 - 12:20pmYOUNG INVESTIGATOR SCHOLARSHIP POSTER SESSION
Poster Abstracts #13-22
12:20pm - 1:20LUNCH
Session V. Commercialization Strategies: Developing Science into Products
Chair: Frank Longo, MD, PhD—Stanford School of Medicine
1:20 - 1:25Session Overview:
Frank Longo, MD, PhD—Stanford School of Medicine
1:25 - 1:45Intellectual Property Strategies: What and When to File for Patent Protection
Leslie Meyer-Leon, JD—IP Legal Strategies Group PC
1:45 - 1:55Q&A
1:55 - 2:15Lessons Learned in Drug Development from an Academic and Small Biotech Perspective
Frank Longo, MD, PhD—Stanford School of Medicine
2:15 - 2:25Q&A
2:25 - 2:45Finding and Working with Investors/Industrial Partners
Rana Quraishi, PhD—UM Ventures, University of Maryland Baltimore
2:45 - 2:55Q&A
2:55 - 3:00pmClosing Remarks:
Howard Fillit, MD—Alzheimer's Drug Discovery Foundation